Ironwood Pharmaceuticals Inc
$ 4.26
2.65%
06 Aug - close price
- Market Cap 683,146,000 USD
- Current Price $ 4.26
- High / Low $ 4.38 / 3.92
- Stock P/E 6.92
- Book Value -1.32
- EPS 0.60
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.33 %
- ROE -5.75 %
- 52 Week High 5.78
- 52 Week Low 0.81
About
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$6.35
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-25 | 2025-11-10 | 2025-08-07 | 2025-05-07 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-09 |
| Reported EPS | 0.14 | 0.24 | -0.01 | 0.24 | 0.14 | -0.14 | 0.02 | 0.02 | -0.0054 | -0.02 | -0.01 | 0.12 |
| Estimated EPS | 0.26 | 0.24 | 0.0168 | 0.12 | -0.02 | -0.03 | 0.0775 | 0.1 | 0.14 | 0.15 | 0.2 | 0.16 |
| Surprise | -0.12 | 0 | -0.0268 | 0.12 | 0.16 | -0.11 | -0.0575 | -0.08 | -0.1454 | -0.17 | -0.21 | -0.04 |
| Surprise Percentage | -46.1538% | 0% | -159.5238% | 100% | 800% | -366.6667% | -74.1935% | -80% | -103.8571% | -113.3333% | -105% | -25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRWD
2026-08-06 12:10:12
Ironwood Pharmaceuticals reported strong second-quarter 2026 results, leading the company to raise its full-year financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA. The company also announced the initiation of the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure (SBS-IF), aiming for it to be the first long-acting GLP-2 analog on the market. These achievements are attributed to strong LINZESS performance, including improved net price and prescription demand growth, and strategic advancements in its pipeline.
2026-07-28 20:41:29
BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc, totaling 13,373,568 shares of Class A stock. BlackRock exercises sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,568 shares. The filing specifies that while various clients may benefit from dividends or sale proceeds, no individual client's interest exceeds five percent of Ironwood's outstanding common shares.
2026-07-27 23:41:29
The article provides financial data specifically focusing on the Return on Assets (%) for Ironwood Pharmaceuticals, Inc. Class A, traded under the symbol I76 on the Hamburg Stock Exchange. It indicates historical values and changes for this metric, noting that the market is currently closed with no trades.
2026-07-27 17:40:06
This article states the total operating expenses for Ironwood Pharmaceuticals, Inc. Class A, traded on the Hamburg Stock Exchange under the ticker I76. It indicates that the market is closed with no current trades. Further financial details would be available in a dedicated "Financials" section not fully displayed here.
2026-07-26 11:10:29
Ironwood Pharmaceuticals, Inc. Class A (I76 BX Swiss) generated 234.78 million CHF last year, primarily from its Human Therapeutics segment. This represents a decrease from the previous year's 319.15 million CHF. The United States was the largest contributor to revenue, accounting for 229.38 million CHF.
2026-07-25 23:47:52
Ironwood Pharmaceuticals, Inc. (SWB:I76) generated €252.15 million in revenue last year, primarily from its Human Therapeutics segment. This marks a decrease from the previous year's €339.45 million, with the United States contributing the majority of the revenue.
